Sclerostin
Synonyms
Sclerostin, UNQ2976/PRO7455/PRO7476, SOST, Sclerosteosis, DAND6, SOST1, VBCH, CDD
Description
Sclerostin is the negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.
KO Status
F1 (+/-)
Drug Information
Launched drug: 1
Drugs in clinical trials: 3
Latest Research Phase: Approved
Drug Name
Code
Phase
Company
Indications
Clinical Trials
Romosozumab
AMG-785, CDP-7851
Approved
Amgen Inc, Ucb Sa
Osteoporosis, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Osteogenesis Imperfecta
Blosozumab
LY-2541546
Phase 2 Clinical
Eli Lilly And Company
Osteoporosis, Osteoporosis, Postmenopausal
Setrusumab
NOV-3, BPS-804, MOR-05813
Phase 2 Clinical
Morphosys, Novartis Pharma Ag
Osteoporosis, Bone Diseases, Metabolic, Hypophosphatasia, Osteogenesis Imperfecta, Renal Insufficiency, Chronic
SHR-1222
SHR-1222
Phase 1 Clinical
Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd
Osteoporosis, Osteoporosis, Postmenopausal
AMG-167
AMG-167
Pending
Amgen Inc
Bone Diseases, Metabolic, Osteoporosis
References
Title
Authors
Source
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans W., Ebeling M., Patel N., van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., van den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P., Dikkers F.G., Stratakis C., Lindpaintner K., Van Hul W.,
Hum. Mol. Genet. 10:537-543(2001)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., Skonier J.E., Zhao L., Sabo P.J., Fu Y.H., Alisch R.S., Gillett L., Colbert T., Tacconi P., Galas D., Hamersma H., Beighton P., Mulligan J.T.,
Am. J. Hum. Genet. 68:577-589(2001)
The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment
Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Gray A.M.,
Genome Res. 13:2265-2270(2003)
DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage
Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., Chang J.L., Nusbaum C.,
Nature 440:1045-1049(2006)
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)
The MGC Project Team,
Genome Res. 14:2121-2127(2004)
Signal peptide prediction based on analysis of experimentally verified cleavage sites
Zhang Z., Henzel W.J.,
Protein Sci. 13:2819-2824(2004)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., Dioszegi M., Dikkers F.G., Hildering P., Willems P.J., Verheij J.B., Lindpaintner K., Vickery B., Foernzler D., Van Hul W.,
J. Med. Genet. 39:91-97(2002)
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor
Semenov M., Tamai K., He X.,
J. Biol. Chem. 280:26770-26775(2005)
Proteomics characterization of extracellular space components in the human aorta
Didangelos A., Yin X., Mandal K., Baumert M., Jahangiri M., Mayr M.,
Mol. Cell. Proteomics 9:2048-2062(2010)
Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia
Kim S.J., Bieganski T., Sohn Y.B., Kozlowski K., Semenov M., Okamoto N., Kim C.H., Ko A.R., Ahn G.H., Choi Y.L., Park S.W., Ki C.S., Kim O.H., Nishimura G., Unger S., Superti-Furga A., Jin D.K.,
Hum. Genet. 129:497-502(2011)